Skip to main content
SpringerLink
Log in
Book cover

Animal Cell Culture pp 717–757Cite as

Biopharmaceutical Products from Animal Cell Culture

  • Chapter
  • First Online:

Part of the book series: Cell Engineering ((CEEN,volume 9))

Abstract

Animal cell culture bioprocesses based on mammalian expression systems have given the pharmaceutical industry a means to produce complex glycosylated therapeutic proteins that is projected to be at least a US$500 billion dollar market by 2020. Medicinal products produced by mammalian cell cultures include hormones, enzymes, cytokines, bone morphogenic proteins, clotting factors, antibodies, and fusion protein therapeutics. Activase®, a recombinant thrombolytic enzyme, was the first approved mammalian cell culture drug to be produced from Chinese hamster ovary cell culture and marketed to the public. Over time, other mammalian derived products followed and have evolved from simple replicas of endogenous proteins to complex engineered bio-molecules. Among the existing mammalian expressed biological drugs discussed, that have been produced in the USA and EU till early 2014, monoclonal antibody therapeutics have become the top earning products being over 40 % of products produced. The development of chimeric, humanized and eventually fully human antibodies has also decreased immunogenic reactions in human patients to below 10 % for the majority of engineered monoclonals with some even reaching below 1 %. Enbrel®, the first Fc-fusion protein introduced onto the market has also led to engineered therapeutic proteins with a longer half-life and multiple functions as with the introduction of bispecific antibody therapeutics. The introduction of the first biosimilars, starting in 2007, can further lower the cost of access to mammalian produced biologics and has also meant a further increase in the overall mammalian cell culture capacity around the globe.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50

    Article  CAS  PubMed  Google Scholar 

  • Baldi L, Muller N, Picasso S, Jacquet R, Girard P, Thanh HP, Derow E, Wurm FM (2005) Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog 21:148–153

    Article  CAS  PubMed  Google Scholar 

  • Barnes LM, Bentley CM, Dickson AJ (2001) Characterization of the stability of recombinant protein production in the GS-NS0 expression system. Biotechnol Bioeng 73:261–270

    Article  CAS  PubMed  Google Scholar 

  • Baxter (2014) Rixubis full prescribing information

    Google Scholar 

  • Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (NY) 10:169–175

    Article  CAS  Google Scholar 

  • Beck A, Wurch T, Corvaïa N (2008) Therapeutic antibodies and derivatives: from the bench to the clinic. Bentham Science Publishers, Bussum, The Netherlands

    Google Scholar 

  • Bouloux PMG, Handelsman DJ, Jockenhövel F, Nieschlag E, Rabinovici J, Frasa WLH, De Bie JJ, Voortman G, Itskovitz-Eldor J, Group*, O. B. O. T. F.-C. S (2001) First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum Reprod 16:1592–1597

    Article  CAS  PubMed  Google Scholar 

  • Butler M (2005) Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 68:283–291

    Article  CAS  PubMed  Google Scholar 

  • Cannon CP, Gibson CM, Mccabe CH, Adgey AAJ, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van De Werf F, Braunwald E, Investigators, F. T. T. I. M. I. B (1998) TNK–tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 98:2805–2814

    Article  CAS  PubMed  Google Scholar 

  • Carvalhal AV, Moreira JL, Carrondo MJ (2001) Strategies to modulate BHK cell proliferation by the regulation of IRF-1 expression. J Biotechnol 92:47–59

    Article  CAS  PubMed  Google Scholar 

  • Chon JH, Zarbis-Papastoitsis G (2011) Advances in the production and downstream processing of antibodies. N Biotechnol 28:458–463

    Article  CAS  PubMed  Google Scholar 

  • Christie A, Butler M (1999) The adaptation of BHK cells to a non-ammoniagenic glutamate-based culture medium. Biotechnol Bioeng 64:298–309

    Article  CAS  PubMed  Google Scholar 

  • Cockett MI, Bebbington CR, Yarranton GT (1990) High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (NY) 8:662–667

    Article  CAS  Google Scholar 

  • Food and Drug Administration (2014) FDA. http://www.fda.gov/. Accessed 5 Apr 2014

  • Duijkers IJM, Klipping C, Boerrigter PJ, Machielsen CSM, De Bie JJ, Voortman G (2002) Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod 17:1987–1993

    Article  CAS  PubMed  Google Scholar 

  • Ecker DM, Ransohoff TC (2014) Mammalian cell culture capacity for biopharmaceutical manufacturing. In: Zhou W, Kantardjieff A (eds) Mammalian cell cultures for biologics manufacturing. Springer, Berlin/Heidelberg

    Google Scholar 

  • European Medicine Agency (2014) EMA [Online]. EMA, London. http://www.ema.europa.eu/ema/. Accessed 5 Apr 2014

  • Fares FA, Suganuma N, Nishimori K, Lapolt PS, Hsueh AJ, Boime I (1992) Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A 89:4304–4308

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Genentech (1997) Rituxan full prescribing information

    Google Scholar 

  • Geserick C, Bonarius HP, Kongerslev L, Hauser H, Mueller PP (2000) Enhanced productivity during controlled proliferation of BHK cells in continuously perfused bioreactors. Biotechnol Bioeng 69:266–274

    Article  CAS  PubMed  Google Scholar 

  • Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A (2012) Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 28:147–175

    Article  CAS  PubMed  Google Scholar 

  • Gillis J, Wagstaff A, Goa K (1995) Alteplase. Drugs 50:102–136

    Article  CAS  PubMed  Google Scholar 

  • Grabowski H, Cockburn I, Long G (2006) The market for follow-on biologics: how will it evolve? Health Aff 25:1291–1301

    Article  Google Scholar 

  • Green LL (1999) Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231:11–23

    Article  CAS  PubMed  Google Scholar 

  • Grillo-Lopez AJ (2000) Rituximab: an insider’s historical perspective. Semin Oncol 27:9–16

    CAS  PubMed  Google Scholar 

  • Harding FA, Stickler MM, Razo J, Dubridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256–265

    Article  PubMed Central  PubMed  Google Scholar 

  • Hendrickson JE, Desmarets M, Deshpande SS, Chadwick TE, Hillyer CD, Roback JD, Zimring JC (2006) Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 46:1526–1536

    Article  CAS  PubMed  Google Scholar 

  • Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ (2008) Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443–2452

    Article  CAS  PubMed  Google Scholar 

  • Huang YM, Hu W, Rustandi E, Chang K, Yusuf-Makagiansar H, Ryll T (2010) Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol Prog 26:1400–1410

    Article  CAS  PubMed  Google Scholar 

  • Hwang WYK, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3–10

    Article  CAS  PubMed  Google Scholar 

  • Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134–1143

    Article  CAS  PubMed  Google Scholar 

  • Jenkins N, Parekh RB, James DC (1996) Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol 14:975–981

    Article  CAS  PubMed  Google Scholar 

  • Kelley B (2009) Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 1:443–452

    Article  PubMed Central  PubMed  Google Scholar 

  • Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, Khan MA, Yanover C, Sauna ZE (2013) Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci 34:534–548

    Article  CAS  PubMed  Google Scholar 

  • Kirchhoff S, Kroger A, Cruz H, Tummler M, Schaper F, Koster M, Hauser H (1996) Regulation of cell growth by IRF-1 in BHK-21 cells. Cytotechnology 22:147–156

    Article  CAS  PubMed  Google Scholar 

  • Knight DM, Wagner C, Jordan R, Mcaleer MF, Derita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J (1995) The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 32:1271–1281

    Article  CAS  PubMed  Google Scholar 

  • Krueger GG, Callis KP (2003) Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 49:S87–S97

    Article  PubMed  Google Scholar 

  • Krueger GG, Ellis CN (2003) Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 148:784–788

    Article  CAS  PubMed  Google Scholar 

  • Kunadian V, Gibson CM (2012) Thrombolytics and myocardial infarction. Cardiovasc Ther 30:e81–e88

    Article  CAS  PubMed  Google Scholar 

  • Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, Blumberg RS (2010) Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 30:777–789

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, Van De Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, Van Rhee F (2013) A phase I, open-label study of Siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin’s lymphoma, multiple myeloma, or Castleman’s disease. Clin Cancer Res 19:3659–3670

    Google Scholar 

  • Kuystermans D, Al-Rubeai M (2011) Bioreactor systems for producing antibody from mammalian cells. In: Al-Rubeai M (ed) Antibody expression and production, 7th edn. Springer, Dordrecht

    Google Scholar 

  • Lanthier M, Behrman R, Nardinelli C (2008) Economic issues with follow-on protein products. Nat Rev Drug Discov 7:733–737

    Article  CAS  PubMed  Google Scholar 

  • Leveque D, Wisniewski S, Jehl F (2005) Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res 25:2327–2343

    CAS  PubMed  Google Scholar 

  • Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, Mccabe JG et al (1994) Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856–859

    Article  CAS  PubMed  Google Scholar 

  • Low D, O’leary R, Pujar NS (2007) Future of antibody purification. J Chromatogr B 848:48–63

    Article  CAS  Google Scholar 

  • Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM (2011) Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents 37:396–404

    Article  CAS  PubMed  Google Scholar 

  • Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS (1994) Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 152:2753–2767

    CAS  PubMed  Google Scholar 

  • Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188–2195

    CAS  PubMed  Google Scholar 

  • Markets and Markets (2011) Strategic analysis & forecast of US biopharmaceutical industry (2009–2016): impact of healthcare reform, technological innovation & market [Online]. Dallas. http://www.marketsandmarkets.com/Market–Reports/biopharmaceutical–323.html. Accessed 4 Apr 2014

  • Marks L (2012) The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin. MAbs 4:403–412

    Article  PubMed Central  PubMed  Google Scholar 

  • Mcguill MW, Rowan AN (1989) Refinement of monoclonal antibody production and animal well-being. ILAR J 31:7–11

    Article  Google Scholar 

  • Milbrandt JD, Azizkhan JC, Hamlin JL (1983) Amplification of a cloned Chinese hamster dihydrofolate reductase gene after transfer into a dihydrofolate reductase-deficient cell line. Mol Cell Biol 3:1274–1282

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561

    CAS  PubMed  Google Scholar 

  • Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, Van Puijenbroek E, Ferrara C, Sondermann P, Jager C, Strein P, Fertig G, Friess T, Schull C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umana P (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393–4402

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Niaudet P, Jean G, Broyer M, Chatenoud L (1993) Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 7:263–267

    Article  CAS  PubMed  Google Scholar 

  • Norman P (2011) Monoclonal antibodies in the pipeline: a segment of major growth report. Cambridge Healthtech Institute, Needham

    Google Scholar 

  • Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759–1769

    Article  CAS  PubMed  Google Scholar 

  • Pfizer (1997) Benefix full prescribing information

    Google Scholar 

  • Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM (2010) Pharmacokinetic and pharmacodynamic modeling of an anti–interleukin-6 chimeric monoclonal antibody (Siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16:1652–1661

    Article  CAS  PubMed  Google Scholar 

  • Quan LD, Thiele GM, Tian J, Wang D (2008) The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat 18:723–738

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76–99

    Article  PubMed Central  PubMed  Google Scholar 

  • Reichert JM (2014) Antibodies to watch in 2014. MAbs 6:5–14

    Article  PubMed  Google Scholar 

  • Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073–1078

    Article  CAS  PubMed  Google Scholar 

  • Research and Markets (2013) Biopharmaceuticals – a global market overview [Online]. Dublin. http://www.researchandmarkets.com/research/mrzjdp/biopharmaceuticals. Accessed 4 Apr 2014

  • Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA (1999) Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res 59:2096–2101

    CAS  PubMed  Google Scholar 

  • Rodewald R (1976) pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 71:666–669

    Article  CAS  PubMed  Google Scholar 

  • Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8:E501–E507

    Article  PubMed Central  PubMed  Google Scholar 

  • Schlaeger EJ, Christensen K (1999) Transient gene expression in mammalian cells grown in serum-free suspension culture. Cytotechnology 30:71–83

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schneider CK, Kalinke U (2008) Toward biosimilar monoclonal antibodies. Nat Biotech 26:985–990

    Article  CAS  Google Scholar 

  • Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin J-H, Weise M, Thirstrup S (2012) Setting the stage for biosimilar monoclonal antibodies. Nat Biotech 30:1179–1185

    Article  CAS  Google Scholar 

  • Sheeley DM, Merrill BM, Taylor LC (1997) Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. Anal Biochem 247:102–110

    Article  CAS  PubMed  Google Scholar 

  • Shire SJ (2009) Formulation and manufacturability of biologics. Curr Opin Biotechnol 20:708–714

    Article  CAS  PubMed  Google Scholar 

  • Shukla AA, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261

    Article  CAS  PubMed  Google Scholar 

  • Shukla AA, Hubbard B, Tressel T, Guhan S, Low D (2007) Downstream processing of monoclonal antibodies–application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848:28–39

    Article  CAS  PubMed  Google Scholar 

  • Shulman M, Wilde CD, Kohler G (1978) A better cell line for making hybridomas secreting specific antibodies. Nature 276:269–270

    Article  CAS  PubMed  Google Scholar 

  • Silverman GJ, Weisman S (2003) Rituximab therapy and autoimmune disorders: prospects for anti–B cell therapy. Arthritis Rheum 48:1484–1492

    Article  CAS  PubMed  Google Scholar 

  • Simister NE, Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337:184–187

    Article  CAS  PubMed  Google Scholar 

  • Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998) Abciximab (ReoPro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αvβ3 integrins. Circulation 98:1085–1091

    Article  CAS  PubMed  Google Scholar 

  • Trotta F, Leufkens HGM, Schellens JHM, Laing R, Tafuri G (2011) Evaluation of oncology drugs at the European medicines agency and US food and drug administration: when differences have an impact on clinical practice. J Clin Oncol 29:2266–2272

    Article  PubMed  Google Scholar 

  • Van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R (2010) Siltuximab, a novel anti–interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol 28:3701–3708

    Article  PubMed  Google Scholar 

  • Vital EM, Emery P (2006) Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2:365–375

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Walsh G (2003) Biopharmaceuticals: biochemistry and biotechnology. Wiley, West Sussex

    Google Scholar 

  • Walsh G (2004) Second-generation biopharmaceuticals. Eur J Pharm Biopharm 58:185–196

    Article  CAS  PubMed  Google Scholar 

  • Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917–924

    Article  CAS  PubMed  Google Scholar 

  • Werner A (2013) Large-scale manufacturing of biopharmaceuticals – speed up the road to market by scale up: the 6X15 000 l BI bioreactors. In: Knäblein J (ed) Modern biopharmaceuticals: recent success stories. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

    Google Scholar 

  • Wilde M, Goa K (1996) Muromonab CD3. Drugs 51:865–894

    Article  CAS  PubMed  Google Scholar 

  • Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B, Hixon D, Joneckis C, Kozlowski S, Rosenberg A, Schrager L, Shacter E, Temple R, Webber K, Winkle H (2007) The FDA’s assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 6:437–442

    Article  PubMed  Google Scholar 

  • Yoon S, Kim Y-S, Shim H, Chung J (2010) Current perspectives on therapeutic antibodies. Biotechnol Bioprocess Eng 15:709–715

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sanford Burnham Medical Research Institute, Protein Production and Analysis Core, 6400 Sanger Road, Medical City, Orlando, FL, 32827, USA

    Darrin Kuystermans

  2. School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin, Ireland

    Mohamed Al-Rubeai

Authors
  1. Darrin Kuystermans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Al-Rubeai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darrin Kuystermans .

Editor information

Editors and Affiliations

  1. University College Dublin, Dublin, Ireland

    Mohamed Al-Rubeai

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kuystermans, D., Al-Rubeai, M. (2015). Biopharmaceutical Products from Animal Cell Culture. In: Al-Rubeai, M. (eds) Animal Cell Culture. Cell Engineering, vol 9. Springer, Cham. https://doi.org/10.1007/978-3-319-10320-4_23

Download citation

Publish with us

Policies and ethics

Search

Navigation